488 [37] Jang S, Kim IS, Youn SW. Chronic graft versus host disease mimicking psoriasis in a patient with hemophagocytic lymphohistiocytosis. Ann Dermatol. 2016;28(1):90–3. [38] Čeović R, Desnica L, Pulanić D, et al. High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft vs host disease. Croat Med J. 2016;57(3):229–238. [39] Hu SW, Myskowski PL, Papadopoulos EB, et al. Chronic cutaneous graft versus host disease simulating hypertrophic lupus erythematosusa case report of a new morphologic variant of graft versus host disease. Am J Dermatopathol. 2012;34(6):e81– 83. [40] Arin MJ, Scheid C, Hübel K, et al. Chronic graft versus host disease with skin signs suggestive of dermatomyositis. Clin Exp Dermatol. 2006;31(1):141–143. [41] Skert C, Patriarca F, Sperotto A, et al. Sclerodermatous chronic graft versus host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica. 2006;91(2):258–261 [42] Palencia SI, Rodríguez Peralto JL, Casta o E, et al. Lichenoid nail changes as sole external manifestation of graft vs. host disease. Int J Dermatol. 2002;41(1):44–45. [43] Martires KJ, Baird K, Steinberg SM, et al. Sclerotic type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood. 2011;118(15):4250–4257. [44] Inamoto Y, Storer BE, Petersdorf EW, et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft versus host disease. Blood. 2013;121(25):5098–5103. [45] Inamoto Y, Martin PJ, Flowers ME, et al. Genetic risk factors for sclerotic graft versus host disease. Blood. 2016;128(11):1516– 1524. [46] Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft versus host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956. [47] Kung EF, Soltani K, Petronic Rosic V. Clinicopathologic challenge. Sclerodermoid graft versus host disease (GVHD) with lichensclerosuslike lesions. Int J Dermatol. 2008 Jul;47(7):655– 657. [48] Hymes SR, Alousi AM, Cowen EW. Graft versus host disease: part I. Pathogenesis and clinical manifestations of graft versus host disease. J Am Acad Dermatol. 2012;66(4):515. [49] Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft versus Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401. [50] Arora M, Cutler CS, Jagasia MH, et al. Late acute and chronic graftversus host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(3):449– 455. [51] Shulman HM, Cardona DM, Greenson JK, et al. NIH Consensus development project on criteria for. clinical trials in chronic graft versus host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant. 2015;21(4):589–603. [52] Pidala J, Kim J, Anasetti C, et al. The global severity of chronic graftversus host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non relapse mortality. Haematologica. 2011;96(11):1678–1684. [53] Jacobsohn DA, Kurland BF, Pidala J, et al. Correlation between NIH composite skin score, patient reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood. 2012;120(13):2545–2552 [54] Cutler CS, Koreth J, Ritz J. Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood. 2017;129(1):22– 29. [55] Flowers ME, Martin PJ. How we treat chronic graft versus host disease. Blood. 2015;125(4):606–615. [56] Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft versus host disease (GVHD): first line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010;16(12):1611–1628. [57] Solomon SR, Sizemore CA, Ridgeway M, et al. Corticosteroid Free Primary Treatment of Chronic Extensive Graft versus Host Disease Incorporating Rituximab. Biol Blood Marrow Transplant. 2015;21(9): 1576–1582. [58] Wang Y, Xu LP, Liu DH, et al. First line therapy for chronic graft versushost disease that includes low dose methotrexate is associated with a high response rate. Biol Blood Marrow Transplant. 2009;15(4):505–511. [59] Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft versus host disease. Blood. 2009;113(21):5074–5082. [60] Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second Line Treatment of Chronic Graft versus Host Disease. Biol Blood Marrow Transplant. 2011;17(1):1–17. [61] Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft versus host disease. Blood. 2009;114:719–722. [62] Faraci M, Ricci E, Bagnasco F, et al. Imatinib melylate as second line treatment of bronchiolitis obliterans after allogenic hematopoietic stem cell transplantation in children. Pediatr Pulmonol. 2020;55(3): 631–637. [63] Arai S, Pidala J, Pusic I, et al. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clin Cancer Res. 2016;22(2):319–327. [64] Olivieri A, Cimminiello M, Corradini P, et al. Long term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid refractory chronic GVHD. Blood. 2013;122(25): 4111–4118. [65] de Masson A, Bouaziz JD, Peffault de Latour R. Limited efficacy and tolerance of imatinib mesylate in steroid refractory sclerodermatous chronic GVHD. Blood. 2012;120(25):5089–5090. [66] Kim H, Kim NH, Kang HJ, et al. Successful long term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD. Pediatr Transplant. 2012;16(8):910–912. [67] Osumi T, Miharu M, Tanaka R, et al. Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD. Bone Marrow Transplant. 2012;47(1):139– 140. [68] Olivieri A., Mancini G., Olivieri J. et al. Nilotinib in steroid refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). Bone Marrow Transplant. 2020. Epub aead of print. [69] Chen GL, Carpenter AP, Broady R, et al. Anti–platelet derived growth factor receptor alpha chain antibodies predict for response to nilotinib in steroid refractory or dependent chronic graft versus host disease. Biol Blood Marrow Transplant. 2018;24:373–380. [70] Couriel DR, Saliba R, Escalan MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment
RkJQdWJsaXNoZXIy ODUzNzk5